Sat 24 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| "An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure " | AstraZeneca | Completed | Dapagliflozin | 3 | D169CC00001 | KKUH |
| An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care | GDRS (MOH) | Ongoing | Hydroxychloroquine sulphate | 3 | version 8 | QCH |
| "ALL SCTped 2012 FORUM Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia" | KAIMRC | Ongoing | BUSULFAN | 3 | CT17/016/R | NGHA-R |
| Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): Randomized, Prospective, Pilot Trial | King Faisal Specialist Hospital and Research Centre | Ongoing | Ketamine | 3 | 2191187 | KFSH & RC-R |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. | Roche | Ongoing | RO7034067 | 2 | BP39056 | KFSH&RC-R |
| A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19 | KAIMRC | Ongoing | Favipiravir | 3 | RC20/220/R | NGHA-R |
| A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19 | KAIMRC | Terminated | Favipiravir | 3 | RC20/174/R | NGHA-R |
| A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole. | Novartis | Rejected | Everolimus + Exemestane VS. Everolimus VS. Capecitabine | 2 | CRAD001Y2201 | KFSH & RC-R |
| A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy | Novartis | Ongoing | Ofatumumab | 3b | COMB157G23101 | King Faisal Specialist Hospital and Research Center (Jeddah) |
| A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS | Roche | Completed | Emicizumab | 3 | MO39129 | KFSH & RC-R |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.